实用临床医药杂志2011，Vol.15Issue(9)：64-66,3.
尼妥珠单抗联合吉西他滨加顺铂方案治疗晚期胰腺癌临床疗效观察
Primary study of nimotuzumab combined with gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
秦苑 1任东 2范宇飞 2刘晓林 2李定纲1
作者信息
- 1. 北京市海淀医院肿瘤,血液科,北京,100080
- 2. 北京市燕化医院,肿瘤科,北京,102500
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and side effects of gemcitabine (GEM) and cisplatin (CDDP) chemotherapy combined with nimotuzumab in advanced pancreatic cancer (APC). Methods From May 2007 to Aug. 2010, sixteen cases of APC were included in this study. Patients were given nimotuzumab 200 mg IV weekly for 8 weeks, and then continued receiving nimotuzumab treatment every two weeks until disease progression or unacceptable toxicity occurred. The chemotherapy was as below: GEM 800～1000 mg/m2 FDR IV, d1 and d8, CDDP 30 mg/m2 IV, d2～d4. It was repeated every 21 days. Results Grade Ⅰ ～ Ⅱ of nausea, vomiting,skin rash and bone marrow suppression were found. Grade Ⅲ of thrombopenia was found in one case. There were 8 cases with PR, 5 cases with SD, 3 cases with PD. Conclusion Nimotuzumab combined with GEM and CDDP regimen was effective and well tolerated in patients with advanced pancreatic cancer. It deserves enlargement of samples and further investigation.关键词
胰腺癌/尼妥珠单抗/联合化疗/靶向治疗/表皮生长因子受体单抗Key words
cancer, pancreatic/ nimotuzumab/ gemcitabine/ cisplatin/ chemotherapy/monoclonal antibody分类
医药卫生引用本文复制引用
秦苑,任东,范宇飞,刘晓林,李定纲..尼妥珠单抗联合吉西他滨加顺铂方案治疗晚期胰腺癌临床疗效观察[J].实用临床医药杂志,2011,15(9):64-66,3.
